

EDITORIAL • RÉDACTION

Editor • Rédacteur

John Hoey (john.hoey@cma.ca)

Senior Deputy Editor • Rédactrice adjointe principale

Anne Marie Todkill (annemarie.todkill@cma.ca)

Deputy Editor (Scientific) • Rédactrice adjointe, Sciences

Jennifer Thomas (jennifer.thomas@cma.ca)

Associate Editors • Rédacteurs associés

Tom Elmslie (telmslie@scohs.on.ca)

Ken Flegel (ken.flegel@muhc.mcgill.ca)

Anita Palepu (anita.palepu@hivnet.ubc.ca)

Erica Weir (erica.weir@utoronto.ca)

Eric Wooltorton (eric.wooltorton@cma.ca)

Nick Barrowman (Biostatistics • Biostatistique)

Editorial Fellow • Boursier en rédaction médicale

James Maskalyk (james.maskalyk@cma.ca)

Ombudsman—Ethicist • Ombudsman-éthicien

John Dossetor (ombudsman@cma.ca)

Managing Editor • Rédacteur administratif

Randy Chafy (randy.chafy@cma.ca)

News Editor

Rédacteur, informations générales

Patrick Sullivan (patrick.sullivan@cma.ca)

Editors • Rédacteurs

Patricia Lightfoot (patricia.lightfoot@cma.ca)

Jennifer Raiche (jennifer.raiche@cma.ca)

Kate Schissler (kate.schissler@cma.ca)

Barbara Sibbald (barbara.sibbald@cma.ca)

Steven Wharry (steve.wharry@cma.ca)

Editorial Administrator • Administratrice de rédaction

Carole Corkery (carole.corkery@cma.ca)

Editorial Assistants • Assistantes à la rédaction

Erin Archibald (erin.archibald@cma.ca)

Wilma Fatica (wilma.fatica@cma.ca)

Melanie Mooy (melanie.mooy@cma.ca)

Joyce Quintal (joyce.quintal@cma.ca)

Translation Coordinator

Coordonnatrice de la traduction

Marie Saumure

Contributing Editors • Rédactrices invitées

Gloria Baker; Charlotte Gray; Peggy Robinson;

Lori Anderson; Ann Bolster

Editorial Board • Conseil de rédaction

Paul W. Armstrong (Edmonton)

Neil R. Cashman (Toronto)

Deborah J. Cook (Hamilton)

David H. Feeny (Edmonton)

William Ghali (Calgary)

Frank R. de Groot (Utrecht, the Netherlands)

Judith G. Hall (Vancouver)

Carol P. Herbert (London)

Alejandro R. Jadad (Toronto)

Jerome P. Kassirer (Boston)

Finlay A. McAlister (Edmonton)

Allison J. McGeer (Toronto)

Harriet L. MacMillan (Hamilton)

David Moher (Ottawa)

Susan Phillips (Kingston)

André Picard (Montreal)

Donald A. Redelmeier (Toronto)

Martin T. Schechter (Vancouver)

Sander J.O. Veldhuyzen van Zanten (Halifax)

Salim Yusuf (Hamilton)

All editorial matter in *CMAJ* represents the opinions of the authors and not necessarily those of the Canadian Medical Association (CMA). The CMA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CMAJ* including editorials, studies, reports, letters and advertisements.

Tous les articles à caractère éditorial dans le *JAMC* représentent les opinions de leurs auteurs et n'engagent pas l'Association médicale canadienne (AMC). L'AMC décline toute responsabilité civile ou autre quant à toute erreur ou omission ou à l'usage de tout conseil ou information figurant dans le *JAMC* et les éditoriaux, études, rapports, lettres et publicités y paraissant.

Drug marketing: Unsafe at any dose?

A great problem of contemporary life is how to control the power of economic interests which ignore the harmful effects of their applied science and technology. — Ralph Nader, *Unsafe at Any Speed*, 1965

Although Ralph Nader's target was the automobile industry, this comment could apply to the pharmaceutical industry today. Drug companies are under intense pressure to balance profit against consumer welfare. Given that it takes roughly US\$600 million to bring a new drug successfully to market, manufacturers need to get the most out of their investment.

Directly or indirectly, pharmaceutical companies finance most of the continuing education of physicians with respect to the use of new drugs. They hire opinion leaders as consultants, underwrite publications such as consensus guidelines and send "detailers" into physicians' offices. And yes, they advertise in medical journals. Aside from print advertising (which is subject to approval by an advertising board), these activities are governed by a voluntary code of practice, a coarsely wired sieve that can strain out incentives the size of a golf club but not always the finer forms of influence.

The problem is that wherever a drug company exerts its business right to represent its own products, self-interest has an opportunity to do its subtle work. This can occur not only in ad copy but also in regulated areas such as product monographs and Dear Healthcare Professional letters. In this issue Catherine Lemièrre and colleagues¹ (see page 1008) report on the confusion resulting after a recent Health Canada approval of a new indication for Advair, a combination aerosol for the management of asthma. The company, Glaxo-SmithKline, began to use the (self-contradicting) phrase "initial maintenance therapy" in its marketing materials.

Physician members of the Asthma Committee of the Canadian Thoracic Society believed that this could be misinterpreted and used to promote Advair as an appropriate therapy for patients with new-onset mild asthma, a use not supported by their current guidelines,² and objected.

A subtle and, we are told, accidental flaw in wording, with important implications for patient care. It raises the question, How can we scrutinize the self-representations of drug companies closely enough? Although print advertising to physicians is regulated in Canada, what is to stop the promotion of off-label indications in company-sponsored CME and by sales reps in physicians' offices?

Over a year ago a coroner's jury recommended that Health Canada mandate pharmaceutical companies to improve their product information on adverse effects and contraindications. Health Canada's plan, a year later, to "communicate with stakeholders" and assess the feasibility "of electronic posting and maintenance of product monographs"³ seems a hesitant way to grasp the nettle.

Patients need a clear and unbiased description of the use and effects of their medications. Physicians need the same in the materials produced for them, not the current laundry list of small-print disclaimers in product monographs. — *CMAJ*

References

1. Lemièrre C, Becker A, Boulet LP, Bowie D, Cartier A, Cockcroft D, et al. Should combination therapy with inhaled corticosteroids and long-acting β_2 -agonists be prescribed as initial maintenance treatment for asthma? *CMAJ* 2002;167(9):1008-9.
2. Canadian Asthma Consensus Group. Canadian asthma consensus report, 1999. *CMAJ* 1999;161(11 Suppl):1-62.
3. Response to the recommendations to Health Canada of the Coroner's Jury Investigation into the death of Vanessa Young. Available: www.hc-sc.gc.ca/english/protection/vanessa_young/key_initiatives.html (accessed 2002 Sept 23).